Sumit A Shah, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shah’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A120808 · Current
Licensed to practise in California · since 2012 · expires 2028-04-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$172,535
Medicare paid this office $172,535 for 402 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 221 | $89,718 | $160 |
| Return visit (30+ min) | 146 | $27,927 | $107 |
| Long return visit (40+ min) | 57 | $14,033 | $122 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 269 | $9,033 | $15 |
| New patient visit (60+ min) | 45 | $8,637 | $192 |
See all 11 services
| Long return visit (40+ min) | 221 | $89,718 | $160 |
| Return visit (30+ min) | 146 | $27,927 | $107 |
| Long return visit (40+ min) | 57 | $14,033 | $122 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 269 | $9,033 | $15 |
| New patient visit (60+ min) | 45 | $8,637 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,232 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,238 | $150 |
| New patient visit (60+ min) | 30 | $4,735 | $158 |
| Return visit (30+ min) | 14 | $1,628 | $74 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 58 | $1,618 | $15 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,154 | $105 |
Who their Medicare patients are
402 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 13% · Women 11% · Also on Medicaid 19% · Health risk score 2.19. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Cancer 75% · Chronic kidney disease 35% · Coronary heart disease 33% · Diabetes 31% · Atrial fibrillation 22% · Heart failure 17% · Depression 14% · COPD 10% · Stroke 9% · Dementia 7%.
The office billed $882,535, Medicare allowed $228,641 and paid $172,535; for 1,877 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 402 | 1,877 | 76 | 2.19 | $882,535 | $172,535 |
| 2023 | 382 | 1,215 | 75 | 1.98 | $750,364 | $140,830 |
| 2022 | 352 | 1,149 | 75 | 2.03 | $773,636 | $131,481 |
| 2021 | 324 | 1,157 | 75 | 2.18 | $724,868 | $132,554 |
| 2020 | 335 | 1,149 | 74 | 2.11 | $531,999 | $107,777 |
| 2019 | 289 | 965 | 75 | 2.30 | $181,517 | $88,421 |
| 2018 | 161 | 561 | 75 | 1.82 | $95,967 | $55,600 |
| 2017 | 82 | 204 | 74 | 1.80 | $56,268 | $22,489 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Long return visit (40+ min) | 185 | $58,798 | $125 |
| Long return visit (40+ min) | 80 | $27,465 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $16,565 | $110 |
| New patient visit (60+ min) | 72 | $10,989 | $153 |
| Return visit (30+ min) | 74 | $9,884 | $82 |
| Return visit (30+ min) | 43 | $5,302 | $75 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,278 | $160 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,928 | $107 |
| New patient visit (60+ min) | 11 | $1,503 | $137 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,023 | $73 |
2022: 9 services
| Long return visit (40+ min) | 180 | $55,013 | $128 |
| Long return visit (40+ min) | 80 | $20,791 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $14,312 | $94 |
| Return visit (30+ min) | 91 | $13,001 | $81 |
| New patient visit (60+ min) | 64 | $10,386 | $162 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,937 | $183 |
| Return visit (30+ min) | 42 | $4,935 | $77 |
| New patient visit (60+ min) | 19 | $2,892 | $152 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,068 | $98 |
2021: 10 services
| Long return visit (40+ min) | 126 | $45,174 | $131 |
| Return visit (30+ min) | 100 | $18,663 | $88 |
| Long return visit (40+ min) | 64 | $18,100 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $12,792 | $95 |
| New patient visit (60+ min) | 66 | $11,161 | $169 |
| Return visit (30+ min) | 55 | $8,662 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $7,046 | $185 |
| Hospital discharge day management, more than 30 minutes | 32 | $3,227 | $101 |
| New patient visit (60+ min) | 16 | $2,880 | $180 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,507 | $79 |
2020: 10 services
| Long return visit (40+ min) | 82 | $20,110 | $99 |
| Return visit (30+ min) | 116 | $18,029 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $14,329 | $97 |
| Return visit (30+ min) | 81 | $12,865 | $67 |
| New patient visit (60+ min) | 79 | $11,731 | $148 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $10,409 | $189 |
| Long return visit (40+ min) | 53 | $10,056 | $95 |
| Hospital discharge day management, more than 30 minutes | 42 | $4,387 | $100 |
| New patient visit (60+ min) | 24 | $3,500 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,078 | $67 |
2019: 10 services
| Long return visit (40+ min) | 108 | $24,658 | $94 |
| Long return visit (40+ min) | 54 | $12,464 | $94 |
| New patient visit (60+ min) | 82 | $11,641 | $142 |
| Return visit (30+ min) | 84 | $10,725 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $9,203 | $93 |
| Return visit (30+ min) | 50 | $8,559 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,979 | $181 |
| New patient visit (60+ min) | 20 | $2,857 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,366 | $65 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,173 | $98 |
2018: 7 services
| Long return visit (40+ min) | 58 | $16,790 | $95 |
| Long return visit (40+ min) | 40 | $12,847 | $95 |
| New patient visit (60+ min) | 66 | $9,731 | $147 |
| Return visit (30+ min) | 38 | $3,603 | $67 |
| Return visit (30+ min) | 28 | $3,532 | $71 |
| New patient visit (60+ min) | 22 | $2,923 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $2,902 | $94 |
2017: 6 services
| Long return visit (40+ min) | 20 | $4,882 | $100 |
| New patient visit (60+ min) | 23 | $3,457 | $150 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,082 | $181 |
| Long return visit (40+ min) | 11 | $2,491 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,057 | $93 |
| New patient visit (60+ min) | 13 | $1,954 | $150 |
Medicaid work
$9,969 in 2024
Medicaid paid $9,969 for 195 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 165 | $9,921 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 30 | $48 |
| 2024 | 195 | 2 | 25 | $9,969 |
| 2023 | 203 | 1 | 24 | $9,746 |
| 2022 | 132 | 1 | 20 | $6,279 |
| 2021 | 105 | 2 | 22 | $3,759 |
| 2020 | 125 | 3 | 16 | $7,328 |
| 2019 | 15 | 1 | 12 | $954 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 203 | $9,746 |
2022
| Long return visit (40+ min) | 132 | $6,279 |
2021
| Long return visit (40+ min) | 65 | $2,463 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 40 | $1,296 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 59 | $4,889 |
| Return visit (30+ min) | 54 | $1,723 |
| Long return visit (40+ min) | 12 | $716 |
2019
| Long return visit (40+ min) | 15 | $954 |
Drugs they prescribed that Part D paid
$1,538,257
Pharmacies billed $1,538,257 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
295 generic and 147 brand-name prescriptions · $1,538,257 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 34 | $483,889 | $14,232 |
| Inlyta | 16 | $330,937 | $20,684 |
| Nubeqa | 15 | $187,517 | $12,501 |
| Abiraterone Acetate | 93 | $154,049 | $1,656 |
| Orgovyx | 28 | $70,814 | $2,529 |
See all 11 drugs
| Xtandi | 34 | $483,889 | $14,232 |
| Inlyta | 16 | $330,937 | $20,684 |
| Nubeqa | 15 | $187,517 | $12,501 |
| Abiraterone Acetate | 93 | $154,049 | $1,656 |
| Orgovyx | 28 | $70,814 | $2,529 |
| Myrbetriq | 24 | $14,442 | $602 |
| Eliquis | 11 | $6,144 | $559 |
| Prednisone | 91 | $376 | $4 |
| Ondansetron | 19 | $196 | $10 |
| Prochlorperazine Maleate | 16 | $172 | $11 |
| Dexamethasone | 12 | $163 | $14 |
Year by year
| 2024 | 442 | 95 | None | 33% | $1,538,257 |
| 2023 | 411 | 85 | None | None | $910,768 |
| 2022 | 475 | 100 | None | None | $768,094 |
| 2021 | 317 | 73 | None | 13% | $242,846 |
| 2020 | 390 | 107 | 3% (13) | 28% | $1,093,004 |
| 2019 | 458 | 89 | 4% (16) | 32% | $1,532,674 |
| 2018 | 327 | 69 | 5% (16) | 36% | $1,086,166 |
| 2017 | 82 | 29 | None | 22% | $76,631 |
| 2015 | 26 | 15 | 81% (21) | None | $1,217 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Cabometyx | 13 | $361,994 | $27,846 |
| Abiraterone Acetate | 98 | $179,584 | $1,832 |
| Orgovyx | 40 | $107,570 | $2,689 |
| Eliquis | 15 | $9,076 | $605 |
| Myrbetriq | 12 | $5,680 | $473 |
| Prednisone | 103 | $792 | $8 |
| Prochlorperazine Maleate | 15 | $167 | $11 |
| Ondansetron | 17 | $127 | $7 |
2022: 7 drugs
| Abiraterone Acetate | 102 | $157,071 | $1,540 |
| Orgovyx | 31 | $80,785 | $2,606 |
| Prednisone | 128 | $1,090 | $9 |
| Tamsulosin | 21 | $560 | $27 |
| Ondansetron | 23 | $319 | $14 |
| Prochlorperazine Maleate | 19 | $225 | $12 |
| Dexamethasone | 15 | $182 | $12 |
2021: 8 drugs
| Abiraterone Acetate | 41 | $57,490 | $1,402 |
| Eliquis | 13 | $7,172 | $552 |
| Prednisone | 47 | $574 | $12 |
| Ondansetron | 24 | $454 | $19 |
| Dexamethasone | 17 | $284 | $17 |
| Prochlorperazine Maleate | 18 | $225 | $12 |
| Amlodipine Besylate | 16 | $58 | $4 |
| Lorazepam | 11 | $52 | $5 |
2020: 9 drugs
| Xtandi | 47 | $510,144 | $10,854 |
| Zytiga | 11 | $120,962 | $10,997 |
| Abiraterone Acetate | 11 | $18,752 | $1,705 |
| Eliquis | 13 | $6,815 | $524 |
| Prednisone | 76 | $562 | $7 |
| Ondansetron | 19 | $294 | $15 |
| Dexamethasone | 14 | $235 | $17 |
| Prochlorperazine Maleate | 18 | $222 | $12 |
| Tamsulosin | 12 | $213 | $18 |
2019: 8 drugs
| Xtandi | 56 | $674,144 | $12,038 |
| Zytiga | 58 | $652,404 | $11,248 |
| Prednisone | 117 | $1,070 | $9 |
| Ondansetron | 32 | $508 | $16 |
| Dexamethasone | 20 | $287 | $14 |
| Prochlorperazine Maleate | 17 | $173 | $10 |
| Amlodipine Besylate | 24 | $91 | $4 |
| Omeprazole | 11 | $69 | $6 |
2018: 5 drugs
| Zytiga | 75 | $768,755 | $10,250 |
| Xtandi | 18 | $204,739 | $11,374 |
| Prednisone | 77 | $651 | $8 |
| Ondansetron | 12 | $134 | $11 |
| Prochlorperazine Maleate | 12 | $67 | $6 |
Money from drug and device companies
$575 in 2025
| 2025 | 4 | 10 | None | $575 |
| 2024 | 1 | 6 | $1,992 | $2,389 |
| 2023 | 2 | 3 | $825 | $1,106 |
| 2022 | 3 | 4 | $2,005 | $2,132 |
| 2021 | 1 | 1 | $3,500 | $3,500 |
| 2020 | 4 | 9 | $8,650 | $8,900 |
| 2019 | 3 | 22 | $15,700 | $19,620 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dendreon Pharmaceuticals | Provenge | $269 | 5 payments
|
| Pfizer | Xtandi | $180 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $106 | 1 payment
|
| ABC Home Medical Supply | None | $20 | 1 payment
|
See all 10 published payments
| Pfizer | Meals · 2025-12-19 | Xtandi | $4 |
| Pfizer | Meals · 2025-10-29 | Xtandi | $27 |
| ABC Home Medical Supply | Meals · 2025-10-06 | None | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Lynparza | $106 |
| Dendreon Pharmaceuticals | Meals · 2025-03-28 | Provenge | $37 |
| Dendreon Pharmaceuticals | Meals · 2025-03-28 | Provenge | $72 |
| Dendreon Pharmaceuticals | Meals · 2025-03-27 | Provenge | $59 |
| Dendreon Pharmaceuticals | Meals · 2025-03-27 | Provenge | $89 |
| Dendreon Pharmaceuticals | Meals · 2025-03-20 | Provenge | $13 |
| Pfizer | Meals · 2025-02-14 | None | $149 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,389
| Pfizer | Padcev | $2,389 | 6 payments
|
2023: $1,106
| Janssen Scientific Affairs | Erleada | $825 | 1 payment
|
| Seagen | None | $281 | 2 payments
|
2022: $2,132
| PAVmed | None | $1,500 | 2 payments
|
| Janssen Biotech | Erleada | $505 | 1 payment
|
| Seagen | None | $127 | 1 payment
|
2021: $3,500
| PAVmed | None | $3,500 | 1 payment
|
2020: $8,900
| Janssen Biotech | Erleada | $3,750 | 6 payments
|
| Seagen | Padcev | $1,840 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $1,750 | 1 payment
|
| Janssen Scientific Affairs | Erleada | $1,560 | 1 payment
|
2019: $19,620
| Janssen Biotech | Erleada | $19,060 | 17 payments
|
| Dendreon Pharmaceuticals | Provenge | $346 | 3 payments
|
| Genentech USA | Tecentriq | $214 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Roche Products Limited · Morpheus UC · 2022 | Their institution | $203,064 |
| Roche Products Limited · Morpheus UC · 2023 | Their institution | $150,291 |
| Roche Products Limited · Morpheus UC · 2024 | Their institution | $137,825 |
| Gilead Sciences, Inc. · Stanford Gilead Sciences Digital Health Advisory Board Program · 2023 | Their institution | $83,070 |
| Gilead Sciences, Inc. · Stanford Gilead Sciences Digital Health Advisory Board Program · 2022 | Their institution | $83,070 |
| Roche Products Limited · Morpheus UC · 2025 | Their institution | $34,410 |
| Roche Products Limited · Morpheus UC · 2021 | Their institution | $32,429 |
| Genentech, Inc. · Imcode004 · 2025 | Their institution | $31,309 |
| Roche Products Limited · Morpheus Muc · 2021 | Their institution | $22,086 |
| E.R. Squibb & Sons, L.L.C. · Ph III Mibc Neoadjuvant 1l Bladder Ido Nivo Chemo · 2019 | Their institution | $1,857 |
Professional record
- NPI
- 1942529227
- Licence
- CA A120808California A120808: Current · expires 2028-04-30
- Trained
- University of California, San Francisco School of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-05-25
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 993 Twin Brook Dr, San Jose, CA, 95126